Thus, the identification and/or development of molecules that can delay anaphase entry, potentially by targeting APC/C-CDC20, may have the ability to enhance the effectiveness of anti-cancer drugs such as paclitaxel, eribulin, vinorelbine or anti-cancer agents that are under clinical development, such as sovilnesib (AMG 650) or VLS-1488 [8]. This evidence concerns the gene CDC20 and cancer.